News

Congress wants to cut $1.5 trillion from innovative companies and threaten the loss of one million jobs in order to fund a multi-trillion-dollar spending bill, according to Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl. This approach would undermine the ability to develop new treatments and jeopardize patient access to life-saving medicines.

Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.

A wave of vaccine mandates has started. The FDA's full OK today may have an effect on the unvaccinated with a wait-and-see attitude and could, according to one expert, open the door to off-label use of the vaccine by clinicians.

The drug savings and greater use of generics that ACO proponents hope for did not materailize.

Survey highlights level of compliance preparedness and increasing skepticism towards new regulations.

Now called Comirnaty, the vaccine is approved for those 16 years and older.

Increasing the practice of evidence-based care is vital to improving the quality and efficiency of care in the U.S. To push more providers to adopt evidence-based medicine, we must reward high-quality patient outcomes - not high volumes.

As IT outsourcing surges, finding the right partner is key. Below are five questions that can get you there.

FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.

Eighty-six percent of nurses said supply chain workflows cause them stress and 85% said documenting supplies is challenging.

Pandemic accelerates adoption of automation in healthcare.

Despite 90% of patients who participated in a TrialJectory survey acknowledging importance of genetic testing, less than half have undergone next-generation sequencing.

The therapy is the first approved for patients with tumors associated with von Hippel-Lindau disease.

Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.

Duplication and other errors can turn population health into a guessing game and waste time and money.

Screening and vaccination against HPV have reduced the incidence of cervical cancer, but researchers say some women are being screened for cervical caner too often — partly because of vaccination.

An estimated 1-6% of all children and adolescents have obstructive sleep apnea.

The first half of 2021 saw 372 deals averaging $39.6 million, which is already more than the total value of the deals done in all of 2020.

Positive trial results were reported in The Lancet last year. The FDA is scheduled (the PDUFA date) to make a decision on the application for approval early next year.

Three differentiators that separate leaders from chasers in virtual health transformation.

Effective January 2023, the organization will switch from Express Scripts to CVS Caremark.

Many people ignored heart disease signs and symptoms during the COVID-19 pandemic — sometimes with grave consequences.

The multiple myeloma therapy now has a permanent J code under Medicare Part B.

Healthcare organization serving 3.5 million people in communities throughout mid-Atlantic region announces vaccine requirement for workforce, board members and guests.

Trials result show that Lyumjev compares favorably to Humalog.

In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.

FDA approval of Lumakras was contingent on a trial testing lower doses. It could usher in a new era of optimal dosing instead of the maximum tolerated dosing.